NCT04788459 - Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions

COVID-19Protection Against COVID-19 and Infections With SARS-CoV- 2COVID-19 Immunisation

Interventions

BIOLOGICAL

COVID-eVax

Plasmid DNA Vaccine for COVID-19

DEVICE

Cliniporator® and EPSGun

IGEA Electroporation Device

Trial Locations (4)

San Gerardo Hospital, Monza

Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples

INMI Lazzaro Spallanzani, Rome

- CRC Centro Ricerche Cliniche di Verona, Verona